- Conditions
- Cutaneous Melanoma
- Interventions
- PV-10 (10% rose bengal disodium), Dacarbazine, temozolomide or talimogene laherparepvec
- Drug
- Lead sponsor
- Provectus Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 12
- States / cities
- San Diego, California • Miami Beach, Florida • Tampa, Florida + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma
- Interventions
- Talimogene Laherparepvec, Immediate surgical resection of melanoma lesion(s)
- Drug · Procedure
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Duarte, California • Orange, California + 17 more
- Conditions
- Melanoma
- Interventions
- Nivolumab, HF10
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Melanoma (Skin), Melanoma Stage IIIb-IVM1a, Metastasis Skin, Tumor Skin, BRAF Gene Mutation
- Interventions
- Talimogene laherparepvec (T-Vec), Dabrafenib (BRAF Inhibitor), Trametinib (MEK Inhibitor)
- Drug
- Lead sponsor
- TriHealth Inc.
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio